Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for uveitis-related macular edema or neovascularization
ChiCTR1900024849Phase 4Completed
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of conbercept in Posterior uveitis (non-infectious), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Best-corrected visual acuity and Central macular thickness. Started Dec 2015; status: completed.
02
Drugs
conbercept
03
Conditions
Posterior uveitis (non-infectious)
Beyond the preview
Go deeper on ChiCTR1900024849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024849.